Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.15281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing ulcerative colitis treatment with traditional Chinese medicine.
World J Clin Cases
October 2024
Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404333, Taiwan.
Article Synopsis
- Inflammatory bowel disease, especially ulcerative colitis (UC), is challenging to treat due to its chronic nature and risks of serious complications.* -
- A recent network meta-analysis indicates that combining traditional Chinese medicine (TCM) formulations with mesalazine improves clinical outcomes like mucosal healing and quality of life while reducing adverse effects compared to using mesalazine alone.* -
- Despite promising results, the editorial emphasizes the need for more robust research, including large-scale trials, to validate TCM's benefits in UC management and develop better clinical guidelines.*
Combination treatment of inflammatory bowel disease: Present status and future perspectives.
World J Gastroenterol
April 2024
Unit of Surgical Research and Training, The 2 Department of Surgery, University of Athens, School of Medicine, Aretaieion Hospital, Athens 11528, Greece.
The treatment of patients with inflammatory bowel disease (IBD), especially those with severe or refractory disease, represents an important challenge for the clinical gastroenterologist. It seems to be no exaggeration to say that in these patients, not only the scientific background of the gastroenterologist is tested, but also the abundance of "gifts" that he should possess (insight, intuition, determination, ability to take initiative, ) for the successful outcome of the treatment. In daily clinical practice, depending on the severity of the attack, IBD is treated with one or a combination of two or more pharmaceutical agents.
View Article and Find Full Text PDFMesalazine-Induced Diffuse Lung Injury in a Patient Without Respiratory Signs and Symptoms.
Maedica (Bucur)
December 2023
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Ibaraki, Japan.
Mesalazine is a drug used to treat ulcerative colitis and Crohn's disease, and is known to rarely cause lung injury. We show herein a unique case who developed this drug-induced injury. A 17-year-old boy presented with fever and anorexia after administration of mesalazine.
View Article and Find Full Text PDFEditorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
Aliment Pharmacol Ther
May 2023
Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
Editorial: 5-aminosalicylic acid fails to impact on irritable bowel syndrome-wrong population, intervention, target or hypothesis?
Aliment Pharmacol Ther
November 2022
Gastroenterology and Hepatology, Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!